Prostate-specific antigen and new related markers for prostate cancer

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 9, 1998, Pages 671-681

  Daher, Rose ^a   Beaini, Mona ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Free prostate specific antigen; Human kallikrein 2; Prostate specific antigen; Prostate specific membrane antigen; Reverse transcriptase polymerase chain reaction

Indexed keywords

KALLIKREIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TUMOR MARKER;

BLOOD LEVEL; BREAST CANCER; CANCER DIAGNOSIS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

FEMALE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TISSUE KALLIKREINS;

EID: 0031693385     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1998.120     Document Type: Review

References (139)

1. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993; 39:181-95.
2. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55:2104-10.
3. Hara M, Koyanangi Y, Inoue T, Fukuyama T. Some physiochemical characteristics of gamma-seminoprotein; an antigenic component specific for human seminal plasma. Jpn J Legal Med 1971; 25:322-4.
4. Sensabaugh GF. Isolation and characterization of a semenspecific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci 1978; 23:106-15.
5. Bélanger A, van Halbuk H, Graves HCB, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate-specific antigen: studies for establishment of international PSA standard. Prostate 1995; 27:187-97.
6. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76:1899-903.
7. Watt KWK, Lu PJ, Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci 1986; 83:3166-70.
8. Frenette G, Tremblay RR, Lazure C, Dube JY. Prostatic kallikrein hk2 , but not prostate-specific antigen (hk3), activates single-chain urokinase-type plasminogen activator, Int J Cancer 1997; 71:897-9.
9. Nixon RG, Brawer MK. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density , velocity and age-specific reference ranges. Br J Urol 1997; 79 Suppl 1:61-7.
10. Petterson K, Piironen T, Seppälä M, Liukkonen L, Christensson A, Matikainen MT, et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map , and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-a1-antichymotrypsin complex. Clin Chem 1995; 41:1480-8.
11. Diamandis EP, Yu H. Editorial: new biological functions of prostate-specific antigen ? J Clin Endocrinol Metab 1995; 80:1515-7.
12. Lilja H. Regulation of the enzymatic activity of prostate-specific antigen and its reaction with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest 1995; 55 Suppl 220:47-56.
13. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 41:1115-20.
14. Kirollos MM. Statistical review and analysis of the relationship between serum prostate-specific antigen and age. J Urol 1997; 158:143-5.
15. Boyce N. New PSA guidlines for African-Americans. Clin Lab News 1996; 22 (10):18.
16. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, et al. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Nat Cancer Inst 1997; 89:134-8.
17. Simsek U, Kutlu S, Yavascaouglu I, Oktay B, Özyurt M. Seasonal variation of prostatic acid phosphate and prostate-specific antigen in patients without prostatic malignancy. Eur Urol 1992; 21 Suppl 1:111-4.
18. Smith DS, Catalona WJ. Rate of change in serum prostate-specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152:1163-7.
19. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate-specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997; 157:2183-90.
20. Matzkin H, Laufer M, Chen J, Hareuveni M, Braf Z. Effect of elective prolonged urethral catheterization on serum prostate-specific antigen concentration. Urology 1996; 48:63-6.
21. Ornstein DK, Rao GS, Smith DS, Ratliff TL, Basler JW, Catalona WJ. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate-specific antigen levels. J Urol 1997; 157:195-8.
22. Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate-specific antigen levels in screening volunteers. J Urol 1997; 157:2179-82.
23. Zisman A, Soffer Y, Siegel YI, Paz A, Lindner A. Post ejaculation serum prostate-specific antigen level. Eur Urol 1997; 32:54-7.
24. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentration. Urology 1997; 50:239-43.
25. Honda SAA, Goldstein AP, Morita T, Sugiyama C, Cody L, Rios CN, et al. Prostate-specific antigen concentrations in serum in acute illnesses. Clin Chem 1996; 42:1785-8.
26. Woodrum D, French C, Shamel B. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48 Suppl 6A:33-9.
27. Piironen T, Petterson K, Suonpää M, Stenman U-H, Oesterling JE, Lövgren T, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to a1-antichymotrypsin in blood samples. Urology 1996; 48 Suppl 6A:81-7.
28. Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995; 55 Suppl 221:32-4.
29. Wener MH, Daum PR, Brawer MK. Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995; 41:1730-7.
30. Blase AB, Sokoloff RL, Smith KM. Five PSA methods compared by assaying samples with different PSA ratios. Clin Chem 1997; 43:843-5.
31. Wu JT. Assay for prostate-specific antigen (PSA): problems and possible solutions. J Clin Lab Analysis 1994; 8:51-62.
32. Nakamura RM. Current and future directions regarding quality assurance and standardization of prostate-specific antigen immunoassays. Cancer 1994; 74:1655-9.
33. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51:222-6.
34. 1-antichymotrypsin. Clin Chem 1993; 39:2098-103.
35. Corey E, Wegner SK, Corey MJ, Vessella RL. Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. Clin Chem 1997; 43:575-84.
36. Prestigiacomo AF, Chen Z, Stamey TA. A universal calibrator for prostate-specific antigen (PSA). Scand J Clin Lab Invest 1995; 55 Suppl 221 : 57-9.
37. Stenman U-H, Leinonen J, Zhang W-M. Standardization of PSA determinations. Scand J Clin Lab Invest 1995; 55 Suppl 221:45-51.
38. 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem 1995; 41:1273-82.
39. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson Per-A, et al. Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154:1090-5.
40. Chen Z, Chen H, Stamey TA. Prostate-specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997; 157:2166-70.
41. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996; 42:1026-33.
42. Cuny C, Pham L, Kramp W, Sharp T, Soriano TF. Evaluation of a two-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. Clin Chem 1996; 42:1243-9.
43. Woodrum DL, French CM, Hill TM, Roman SJ, Slatore HL, Shaffer JL, et al. Analytical performance of the Tandem - R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem 1997; 43:1203-8.
44. Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997; 43:1588-94.
45. Prestigiacomo AF, Lilja H, Petterson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate-specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996; 156:350-4.
46. Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate-specific antigen ratio improves the specificity of prostate-specific antigen in screening for prostate cancer in the general population. J Urol 1997; 157:2191-6.
47. Van Cangh PJ, Nayer PD, Vischer LD, Sauvage P, Tombal B, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA. Urology 1996; 48 Suppl 6A:67-70.
48. Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, et al. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 1996; 48 Suppl 6A:45-50.
49. Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology 1996; 48 Suppl 6A:4-9.
50. Morgan TO, Mclead DG, Leifer ES, Murphy GP, Moul JW. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48 Suppl 6A:76-80.
51. Demura T, Shinohara N, Tanaka M, Enami N, Chiba H, Togashi M, et al. The proportion of free to total prostate-specific antigen. Cancer 1996; 77:1137-43.
52. Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH. Comparisons of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology 1996; 48 Suppl 6A:23-32.
53. Littrup PJ. Future benefits and cost effectiveness of prostate cancer screening. American Cancer Society. Cancer 1997; 80:1864-70.
54. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. Cancer 1995; 77:1342-8.
55. Austin OJ, Valente S, Hasse LA, Kues JR. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. Arch Fam Med 1997; 6:453-8.
56. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess Winch Eng 1997; 1(1):1-96.
57. Villers A, Grosclaude P, Haillot O, Abbou CC, Richard F, Boccon Gibod L. Diagnosis of cancer of the prostate (I): advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology. Prog Urol 1997; 7 (3):508-15.
58. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology 1995; 46:773-8.
59. Reissigl A, Klocker H, Pointner J, Fink K, Horninger W, Ennemoser O, et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996; 48 Suppl 6A:62-6.
60. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratlift TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 1995; 274:1214-20.
61. Smitt MC, Heltzel M. The results of radical prostatectomy at a community hospital during the prostate-specific antigen era. Cancer 1996; 77:928-33.
62. Yu Lao GL; Friedman M, Yao SL. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate-specific antigen testing. J Urol 1997; 157:2219-22.
63. Hachiya T, Endo M, Nogaki J, Ishida H, Okada K. Significance of prostate-specific antigen after radical prostatectomy. Int J Urol 1997; 4:461-6.
64. Nadler RB, Andriole GL. Who is best benefited by radical prostatectomy?. Hematol Oncol Clin North Am 1996; 10:581-93.
65. du Fosse W, Billiet I, Mattelaer J. Radical prostatectomy and prognostic factors. Acta Urol BeIg 1997; 65:53-62.
66. Critz FA, Levinson AK, Williams WH, Holladay DA. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 1996; 14:2893-900.
67. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996; 47:232-5.
68. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395-406.
69. Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 1997; 49:737-42.
70. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998; 73:401-6.
71. Sanders H, Graham SD Jr. Comparison of four automated prostate-specific antigen assays for detection of recurrence after radical prostatectomy. Urology 1997; 49:894-7.
72. Stamey TA. Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin Chem 1996; 42:849-52.
73. Diamandis EP, Yu H, Melegos DN. Ultrasensitive prostate-specific antigen assays and their clinical application. Clin Chem 1996; 42:853-7.
74. Vessella RL, Noteboom J, Lange PH. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 1992; 38:2044-54.
75. Klee GG, Dodge LA, Zincke H, Oesterling JE. Measurement of serum prostate-specific antigen using IMx prostate-specific antigen assay. J Urol 1994; 151:94-8.
76. Stamey TA, Graves HCB, Wehner N, Ferrari M, Freiha FS. Early detection of residual cancer after radical prostatectomy by an ultrasensitive assay for prostate-specific antigen. J Urol 1993; 149:787-92.
77. Prestigiacomo AF, Stamey TA. A comparison of 4 ultrasensitive prostate-specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol 1994; 152:1515-9.
78. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate-specific antigen monitoring at levels of 0.001 to 0.1 microG./L. J Urol 1997; 157:913-8.
79. Witherspoon LR, Lapeyrolerie T. Sensitive prostate-specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997; 157:1322-8.
80. van lersel MP, Thomas CM, Segers MF, Witjes WP, Debruyne FM, Oosterhof GO. The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy. Br J Urol 1996; 77:418-22.
81. Moreno JG, Croce CM, Fisher R, Monne M, Vihko P, Mulholland G, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52:6110-2.
82. Boyce N. New technologies aid in prostate cancer prognosis. Clin Lab News 1996; 22 (10):1-18.
83. Galvan B, Christopoulos TK. Quantitative reverse transcriptase-polymerase chain reaction for prostate-specific antigen mRNA. Clin Biochem 1997; 30:391-7.
84. Corey E, Arfman EW, Liu AY, Vessells RL. Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem 1997; 43:443-52.
85. Henke W, Jung M, Jung K, Lein M, Schlechte H, Berndt C, et al. Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells. Clin Chem 1996; 42:1499-50.
86. Zhang Y, Zippe CD, Van Lente F, Klein EA, Gupta MK. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Can Res 1997; 3:1215-20.
87. Moreno JG, O'Hara SM, Long JP, Veltri RW, Ning X, Alexander AA, et al. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR. Urology 1997; 49:515-20.
88. Goldman HB, Israeli RS, Lu Y, Lerner JL, Hollabaugh RS, Steiner MS. Can prostate-specific antigen reverse transcriptase-polymerase chain reaction be used as a prospective test to diagnose prostate cancer ? World J Urol 1997; 15:257-61.
89. Ignatoff JM, Oefelein MG, Watkin W, Chmiel JS, Kaul KL. Prostate-specific-antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 1997; 158:1870-4; discussion 1874-5.
90. De Cremoux P, Ravery V, Podgorniak MP, Chevillard S, Toublanc M, Thiounn N, et al. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol 1997; 32:69-74.
91. Thiounn N, Saporta F, Flam TA, Pages F, Zerbib M, Vieillefond A, et al. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology 1997; 50:245-50.
92. Sardi I, Piazzini M, Ponchietti R, Fatini C, Di-Loro F, Guazzelli R. The use of RT-"nested" PCR of prostate-specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma. J Mol Med 1997; 75:751-7.
93. Ennis RD, Katz AE, de Vries GM, Heitjan DF, O'Toole KM, Rubin M, et al. Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics. Cancer 1997; 79:2402-8.
94. Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997; 50:100-5.
95. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk cancer. J Natl Cancer Inst 1997; 89:1498-504.
96. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate-specific antigen in the management of prostate cancer. J Urol 1997; 158:326-37.
97. Deguchi T, Yang M, Ehara H, Ito S, Nishino Y, Takahashi Y, et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 1997; 75:634-8.
98. Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997; 15:3451-7.
99. Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, et al. Limitations of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15:2701-8.
100. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, et al. Evaluation and comparison of two new prostate carcinoma markers. Free-Prostate-specific antigen and prostate-specific membrane antigen. Cancer 1996; 78:809-18.
101. Noguchi M, Miyajima J, Itoh K, Noda S. Detection of circulating tumor cells in patients with prostate-specific membrane-derived primers in the polymerase chain reaction. Int J Urol 1997; 4:374-9.
102. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate 1997; 32:140-8.
103. Su SL, Heston WD, Perroti M, Cookson MS, Stroumbakis N, Huyrk R, et al. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology 1997; 49 Suppl 3A:95-101.
104. Olsson CA, de Vries GM, Buttyan R, Katz AE. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am 1997; 24:367-78.
105. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CYF, et al. Human glandular kallikrein 2 (hk2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997; 49:857-62.
106. Ferola R, Piironen T, Pettersson K, Lövgren J, Vehniainen M, Lilja H, et al. Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. Prostate 1997; 31:84-90.
107. Villoutreix BO , Lilja H , Pettersson K, Lovgren T, Teleman O. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Protein Sci 1996; 5:836-51.
108. Kumar A, Goel AS, Hill TM, Mikolojczyk SD, Millar LS, Kuus RK, et al. Expression of human glandular kallikrein, hk2, in mammalian cells . Cancer Res 1996; 56:5397-402.
109. Herrala A, Kurkela R, Porvari K, Isomaki R, Henttu P, Vihko P. Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. Clin Chem 1997; 43:279-84.
110. Grauer LS, Charlesworth MC, Saedi MS, Finlay JA, Liu RS, Kuus RK, et al. Identification of human glandular kallikrein hk2 from LNCaP cells. J Androl 1996; 17:353-9.
111. Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, et al. Expression of human prostate-specific glandular kallikrein protein (hk2) in the breast cancer cell line T47-D. Cancer Res 1997; 57:2651-6.
112. Murtha P, Tindall DJ, and Young CY. Androgen induction of human prostate-specific kallikrein, hklk2: characterization of an androgen response element in the 5′ promotor region of the gene. Biochemistry 1993; 32:6459-64.
113. Sun Z, Pan J, Balk SP. Androgen receptor-associated protein complex binds upstream of the responsive elements in the promotors of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res 1997; 25:3318-25.
114. Frenette G, Deperthes D, Tremblay RR, Lazure C, Dube CY. Purification of enzymatically active kallikrein hk2 from human seminal plasma. Biochim Biophys Acta 1997; 1334:109-15.
115. Deperthes D, Chapdelaine P, Tremblay RR, Brunei C, Berton J, Hebert J, et al. Isolation of prostatic kallikrein hk2 , also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995; 1245:311-6.
116. rd edn, pp 277-8, W H Freeman, New York, 1988.
117. Ju H, Dixon IM. Extracellular matrix and cardiovascular diseases. Can J Cardiol 1996; 12:1259-67.
118. Deperthes D, Frenette G, Brillard Bourdet M, Bourgeois L, Gauthier F, Tremblay RR, et al. Potential involvement of kallikrein hk2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996; 17:659-65.
119. Frenette G, Tremblay RR, Lazure C, Dube JY. Prostatic kallikrein hk2, but not prostate-specific antigen (hk3), activates single-chain urokinase-type plasminogen activator, Int J Cancer 1997; 71:897-9.
120. Charlesworth MC, Young CY, Klee GG, Saed MS, Mikolajczyk SD, Finlay JA, et al. Detection of a prostate-specific protein, human glandular kallikrein (hk2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997; 49:487-93.
121. Tremblay RR, Deperthes D, Tetu B, Dube JY. Immunohistochemical study suggesting a complementary role of kallikreins hk2 and hk3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 1997; 150:455-9.
122. Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T. Detection of prostate cancer cells circulating in peripheral blood by reverse transcription for PCR hKLK2. Cancer Res 1997; 57:4167-70.
123. Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CY, et al. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hk2) and prostate-specific antigen (PSA) messages. Urology 1997; 50:184-8.
124. Oesterling JE. Prostate-specific antigen: a critical assesment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145:907-23.
125. Diamandis ER Prostate-specific antigen new applications in breast and other cancers. Anti Cancer Res 1996; 16 Suppl 6C:3983-4.
126. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24:278-82.
127. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55:2104-10.
128. Zarghami N, Levseque M, D'Costa M, Angelopoulou K, Diamandis EP. Frequency of expression of prostate-specific antigen mRNA in lung tumors. Am J Clin Path 1997; 108:184-90.
129. Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P, Luderer AA. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer 1996; 74:871-3.
130. Melegos DN, Diamandis EP. Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem 1996; 29:193-200.
131. Diamandis EP, Yu H, Lopez-Otin C. Prostate-specific antigen-a new constituent of breast cyst fluid. Breast Cancer Res Treat 1996; 38:259-64.
132. Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997; 76:1087-9.
133. Yu H, Diamandis EP, Zarghami N, Grass L. Induction of prostate-specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994; 32:291-300.
134. Zarghami N, Grass L, Diamandis EP. Steroid Hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 1997; 75:579-88.
135. Lai LC, Erbas H, Lennard TW, Peaston RT. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 1996; 66:743-6.
136. Melegos DN, Yu H, Allen LC, Diamandis EP. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 1996; 29:555-62.
137. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG. Biological effects of prostate-specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142:407-15.
138. Watt KWK, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83:3166-70.
139. Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996; 48:317-25.